Asia-Pacific CRO Novotech signs MOU with Taiwanese hospital

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)
Novotech has signed a Memorandum of Understanding (MOU) with the China Medical University Hospital (CMUH) in Taiwan.

The Australia-headquartered contract research organization (CRO) Novotech have five MOUs with major health providers.

Per its agreement with the CMUH, the hospital will provide Novotech’s team with “professional and medical clinical trial advice,”​ including feasibility, principal investigator selection, and patient recruitment support.

Conversely, Novotech will promote CMUH’s clinical research capabilities, specifically its Phase I unit.

The CMUH has 2,054 beds and a dedicated Clinical Trials Center (CTC), which joined the "International Clinical Trials Center Network" (ICN) in 2016.

The ICN includes Zurich University, Harvard University, Cambridge University, and the University of Hong Kong.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us


View more